5 Under-the-Radar AI Stocks to Buy in 2026

In this article, we will discuss the 5 Under-the-Radar AI Stocks to Buy in 2026. For deeper discussion and analysis, read 10 Under-the-Radar AI Stocks to Buy in 2026.

5. iBio, Inc. (NASDAQ:IBIO)

Number of Hedge Fund Holders: 16

On June 8, Raymond James initiated coverage of iBio, Inc. (NASDAQ:IBIO) with an Outperform rating and a $5 price target, highlighting the company’s emerging obesity-focused pipeline and attractive risk-reward profile. The firm pointed to IBIO-600, which recently entered clinical development, as well as IBIO-610, a follow-on candidate that may differentiate itself through higher levels of Activin E inhibition compared with competing INHBE-targeting approaches. According to Raymond James, the company’s valuation does not fully reflect the potential of its pipeline, particularly as demand for innovative obesity and cardiometabolic therapies continues to expand.

Earlier, on June 2, iBio, Inc. (NASDAQ:IBIO) announced the dosing of the first participant in its Phase 1 clinical trial evaluating IBIO-600, marking a major milestone for the company. The candidate is iBio’s lead obesity and cardiometabolic asset and represents the company’s first program to enter human clinical testing. The achievement formally transitions iBio from a preclinical biotechnology company to a clinical-stage developer, providing investors with a key catalyst that could generate additional value as clinical data emerges over the coming quarters.

iBio, Inc. (NASDAQ:IBIO) is an AI-driven biotechnology company focused on discovering and developing precision antibody therapies for obesity, diabetes, cardiometabolic diseases, and oncology indications. Founded in 2008 and headquartered in San Diego, California, the company combines artificial intelligence-driven drug discovery tools with advanced biologics development capabilities to identify novel therapeutic candidates targeting large and underserved healthcare markets.